Providing free continuous glucose monitors to improve diabetes management
Official title: CGMs for All: Studying the Impact of Expanding CGM Access
Run by Yale University · NCT06658067 · Data updated 2026-11-12
This study is testing if giving free continuous glucose monitors to adults with poorly controlled type 2 diabetes can help them manage their blood sugar better and improve their quality of life.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 17 (estimated) |
| Sponsor | Yale University Academic / other |
| Locations | 1 site (New Haven, Connecticut) |
| Status | Recruiting |
| Started | November 12, 2024 |
| Main results expected | June 2026 |
| Study ends | June 2026 |
| Registry record updated | December 3, 2025 |
| Trial ID | NCT06658067 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with type 2 diabetes, an A1c of 8.0 or greater, and who are unable to afford continuous glucose monitors.
✕Probably not a fit
Patients who have well-controlled diabetes or those who can afford CGM sensors may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study examines the effects of providing continuous glucose monitors (CGMs) at no cost to adult patients with poorly controlled type 2 diabetes. Participants will be selected from Fair Haven Community Health Care and must have an A1c of 8.0 or greater while being unable to afford CGM sensors. The study will assess changes in glycemic control and quality of life over a 12-week period, with follow-up visits to adjust medication based on CGM data. The goal is to determine if access to CGMs can improve health outcomes for economically disadvantaged patients.
Why it matters
Potential benefit: If successful, this study could significantly enhance glycemic control and quality of life for patients with type 2 diabetes who currently lack access to necessary monitoring tools.
How similar studies have gone: Other studies have shown positive outcomes with similar interventions, indicating that providing CGMs can improve diabetes management in underserved populations.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Diagnosed with type 2 diabetes mellitus * A1c greater than or equal to 8.0 within two weeks of the time of enrollment * On insulin for at least one year +/- other antihyperglycemics * Ability and willingness to wear CGM for 14-day periods throughout the trial period * Ability and willingness to comply with provider-directed adjustments to medication regimen * Inability to afford CGM sensors A note on Vulnerable Populations: Many of FHCHC's patients are economically disadvantaged and of minority backgrounds; the clinic's patient base may be considered to constitute a vulnerable population. As such, recruitment and enrollment will be conducted within a vulnerable population. The nature of the study requires this, and the results are intended to directly benefit this population through the potential for improved glycemic control and quality of life. Exclusion Criteria: * Insulin naïve * Diabetic ketoacidosis (DKA) in previous 6 months * End-Stage Renal Disease (ESRD) * Contraindications to CGM use * Active insurance plan that would provide enough of a subsidy for participant to feasibly purchase CGM sensors * Pregnancy
Where it's running
-
Fair Haven Community Health Care (FHCHC)
New Haven, Connecticut, United States Recruiting
Study contacts
- Principal investigator: Kasia Lipska, MD MHS — Yale University
- Study coordinator: Justin A Dower, MD
- Email: justin.dower@yale.edu
- Phone: (973) 901-4431
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Family Good Health Traditions for Life program
This program will try a community-tailored, family-based version of the Diabetes Prevention Program to help Black parents with prediabetes and their children lower weight and reduce diabetes risk.
-
Semaglutide's effects on heart and muscle mass
This project will use MRI scans and strength tests over 12 months to see if semaglutide changes body and heart muscle in adults starting the medication.
-
Cognitive screening and multidomain care to slow memory and thinking decline in older adults with type 2 diabetes
This study will test whether regular cognitive screening plus a two-year program of medication optimization, adjusted HbA1c targets, vascular risk management, lifestyle changes, and social support can slow cognitive decline in people aged 65 and older with type 2 diabetes.
-
iLet Bionic Pancreas started through primary care for adults on insulin
This project will test whether starting the iLet Bionic Pancreas through primary care helps adults with insulin-treated type 1 or type 2 diabetes lower their A1c more than routine care over 13 weeks.
-
Foot sensation training to help balance, gait, and function in adults with type 2 diabetes and neuropathy
This randomized trial tests whether foot sensory training, in addition to education, improves balance, walking, and functional ability for adults with type 2 diabetes and neuropathy.
-
Using stem cells to treat difficult cases of Type 2 diabetes
This study is testing whether injecting special stem cells can help people with hard-to-treat Type 2 diabetes better manage their blood sugar along with their usual medications.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.